Perinnöllisten tekijöiden vaikutus diabeteslääkkeisiin 3.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002835-25-FI

Enrollment

Registered

2006-05-22

Start date

2006-08-01

Completion date

Unknown

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Terveet vapaaehtoiset

Interventions

Trade Name: Novonorm Product Name: Novonorm Pharmaceutical Form: Tablet INN or Proposed INN: Repaglinidi Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026